Bayer is beefing up its cancer drug pipeline again. The German pharma company has bought in to an androgen receptor inhibitor therapy being developed at Finland's Orion, paying €50 million in an upfront payment and committing itself to a slate of unspecified milestones.
In this week's EuroBiotech Report, Bayer became the most recent biopharma to tap Dutch biotech arGEN-X for its llama-based antibody discovery platform; Eli Lilly made its first-ever investment in a British venture fund; and British biotech Oxford BioMedica hopes to raise £25.7 million to finance its gene therapy pipeline. And more.
The Netherlands' arGEN-X has paired up with Bayer, agreeing to share its proprietary antibody technology with the drug giant to fuel some early-stage R&D.
Bayer and Boehringer Ingelheim outlined plans to increase access to their clinical trial data.
The company announced on May 15 that it is acquiring Bayer AG's interventional division for $415 million to bulk up on devices for the treatment of peripheral vascular disease.
It turns out that Boehringer Ingelheim's popular anticoagulant Pradaxa is safer than many people think. That is the finding of the FDA after taking another look at the side effects of the drug compared to the old standard warfarin and this time looking at a much larger and older patient base.
Payers worried about hepatitis C drug prices have been counting on impending price competition to save them money. The idea is that, once Merck, AbbVie and Bristol-Myers Squibb have treatments on the market, Gilead Sciences will have to back off its $84,000-per-treatment-course sticker price. The reality could be a little better--and a little worse--than that.
Digital health may be popular in the rest of the healthcare industry, but it's still the red-headed stepchild of pharma marketing. As Mobihealth News reports, providers and payers "have dived into the digital health world with gusto," but pharma's moves haven't been so enthusiastic. Is a new initiative from Bayer any different?
IMS Health has found that a group of cancer treatments launched over the past three years "are following the same trajectory" as blockbusters such as Roche's Avastin, Novartis' Gleevec, Bayer's Nexavar, and Merck Serono's Erbitux--at least so far.
Merck plans to use the proceeds of its planned $14.2 billion consumer business sale to Bayer to beef up its pipeline, and the in-transition pharma giant isn't wasting any time, signing a billion-dollar deal with its new partner in a move to get its hands on some new cardiovascular drugs.